FindTrial
Sign In

Oral Antifibrotic Agents in Pulmonary Fibrosis

Oral Antifibrotic Agents in Pulmonary Fibrosis - Oral Antifibrotic Agents in Pulmonary Fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000058009
Enrollment
400
Registered
2025-05-29
Start date
2025-05-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Fibrosis (IPF/PPF)

Interventions

None listed

Sponsors

Kanagawa Cardiovascular and Respiratory Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. RCT 2. Diagnosis with Pulmonary Fibrosis 3. Oral Antifibrotic Agents

Exclusion criteria

Exclusion criteria: 1. Subgroup analysis without adding new information 2. Data not available

Design outcomes

Primary

MeasureTime frame
FVC—

Countries

Japan,Asia(except Japan),North America,South America,Australia,Europe,Africa

Contacts

Public ContactYoichi Tagami

Kanagawa Cardiovascular and Respiratory Center Department of Respiratory Medicine,

abroadhp@gmail.com045-701-9581

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026